Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
D1000078 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition |
| 2 | EXPERIMENTAL | D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition |
| 3 | EXPERIMENTAL | D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition |
| 4 | EXPERIMENTAL | D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition |
| 5 | EXPERIMENTAL | D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition |
| 6 | EXPERIMENTAL | D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition |
| Name | Type | Description |
|---|---|---|
| D1000078 | DRUG | Oral, one single dose |
| D1000082 | DRUG | Oral, one single dose |
| D1000083 | DRUG | Oral, one single dose |
| D1000085 | DRUG | Oral, one single dose |
Inclusion Criteria: * Ethnic origin: Caucasian * Body-mass index (BMI): ≥ 19 kg/m² and ≤ 27 kg/m² * Good health * Written informed consent, after having been informed about benefits and potential risks of the trial Exclusion Criteria: * Diseases which could influence the gastric emptying and gast...
D1000078 is an investigational small molecule being studied for Magnetic Marker Monitoring, a technique used to track gastrointestinal transport. It is being evaluated in the gastrointestinal therapeutic area to measure gastric emptying time, small intestinal transit time, and time for colon arrival, including the effect of food on these parameters.
D1000078 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in early-stage clinical development.
D1000078 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and effects in humans.
D1000078 has one completed clinical trial registered as NCT01224587, titled "Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions." This Phase 1 study enrolled 5 healthy male volunteers in Germany and was a controlled, randomized trial.
D1000078 is a small molecule used in Magnetic Marker Monitoring, a method that tracks the movement of a magnetically labeled tablet through the gastrointestinal tract. It is used to measure gastric emptying time, small intestinal transit time, and time for colon arrival, including the effect of food on these parameters.